Boston Scientific(BSX) ZACKS·2025-01-09 13:56Company Overview - Boston Scientific Corporation (BSX) has entered into a definitive agreement to acquire Bolt Medical, Inc., a developer of an advanced laser-based intravascular lithotripsy (IVL) platform, which will enhance BSX's cardiovascular portfolio with a complementary calcium modification platform [1] - The acquisition is expected to be completed in the first half of 2025, pending customary closing conditions [1] Financial Details - BSX currently holds a 26% equity stake in Bolt Medical and will make an upfront payment of approximately 221 million based on regulatory milestones [5] - BSX has a market capitalization of 95.95 [2] - Over the past year, BSX's shares have risen by 62%, significantly outperforming the industry growth of 8.1% [11] Industry Prospects - The intravascular lithotripsy market was valued at 659.42 million by 2037, with a compound annual growth rate (CAGR) of approximately 9.1% from 2025 to 2037 [9] - The growth in this market is driven by the increasing prevalence of cardiovascular diseases, influenced by unhealthy lifestyles, dietary changes, and an aging population [9] Recent Strategic Acquisitions - In 2024, BSX completed strategic acquisitions including Silk Road Medical for 3.7 billion, which have contributed to boosting the company's top line [3] - Additionally, BSX has entered into agreements to acquire Intera Oncology Inc. and Cortex, Inc. to expand its interventional oncology offerings and diagnostic mapping solutions, respectively [10] Product Development - Bolt Medical's IVL system utilizes lithotripsy to fracture calcium through acoustic pressure waves within a balloon catheter, and it has recently completed pivotal clinical trials for treating peripheral artery disease [6] - The FDA approved Bolt Medical to commence the global FRACTURE IDE clinical trial for the Bolt IVL Coronary System, targeting coronary arterial disease with severely calcified lesions [7]